The CHAMP phase 3 study showed that NVK002 atropine 0.01% (Vyluma Inc.) “meaningfully slowed” myopia progression in myopic pediatric patients over a 36-month period, according to Rupa K. Wong, MD, who presented the study findings at the annual meeting of the American Association for Pediatric Ophthalmology and Strabismus. Myopia has become a global public health threat and extensive efforts are underway worldwide to identify treatments to control progression. The use of atropine in various concentrations has been evaluated in a number of studies. Read more: https://ow.ly/WacM50Sx8w5
About us
As aging patients increase in number, ophthalmologists and optometrists face regulatory obstacles, reimbursement delays, and limited resources for technology. The tools and knowledge we provide to eyecare professionals help improve the delivery of progressive eye health from provider to patient.
- Website
-
http://ophthalmologytimes.com/
External link for Ophthalmology Times
- Industry
- Media Production
- Company size
- 501-1,000 employees
- Headquarters
- Cleveland , OH
- Type
- Public Company
- Specialties
- Ophthalmology, Eyecare, Glaucoma, Cataract, Refractive, and Retina
Locations
-
Primary
Cleveland , OH, US
Employees at Ophthalmology Times
Updates
-
Digitally guided systems, which relieve surgeons from using goniolenses, facilitate more accurate and faster performance of minimally invasive glaucoma surgery (MIGS) procedures by more surgeons. These benefits, in turn, translate to more consistent and better outcomes for both surgeons and patients, according to lead author Michael Berlin. Berlin is the founder and director of the Glaucoma Institute of Beverly Hills Research Foundation and a clinical professor at the University of California, Los Angeles Stein Eye Institute. Read More: https://ow.ly/RmJ850SwTIU
Goniolens-free guidance systems for ELT: Less proves to be more
ophthalmologytimes.com
-
Andrew Lee, MD, and Andrew Carey, MD, sit down on another episode of the NeuroOp Guru to discuss a unique case of a 15-year-old who showed signs of meningioma with epithelial whirls and some psammoma bodies in the eye. Watch: https://ow.ly/hZmZ50SwTxv
VLOG: NeuroOp Guru: Unique case of 15-year-old who showed signs of meningioma in eye
ophthalmologytimes.com
-
Genentech announced the FDA has approved faricimab-svoa (Vabysmo) 6.0 mg single-dose prefilled syringe (PFS) for use in the treatment of wet, or neovascular, age-related macular degeneration (AMD), diabetic macular edema (DME) and macular edema following retinal vein occlusion (RVO). The single-dose prefilled syringe offers the same medication as existing Vabysmo vials, and offers physicians an alternative, ready-to-use option. It will continue to be available in a 6.0 mg vial. Read More: https://ow.ly/Z9Jf50SwTvC
FDA approves faricimab-svoa 6.0 mg single-dose prefilled syringe for use in the treatment of wet AMD, DME and RVO
ophthalmologytimes.com
-
Test evaluates, quantifies ocular dominance for robust monovision correction. The SimVis Gekko eye dominance strength test may change the standard of care. Read More: https://ow.ly/j5SY50StOXl
-
-
Alcon has announced the closing of its deal to acquire BELKIN Vision which includes a total upfront consideration of $81 million, including a cash payment of approximately $65 million. Read More: https://ow.ly/4FWH50StOc4
-
-
In the Ophthalmology Times Case of the Quarter series, Katherine Talcott, MD, shared 2 cases of geographic atrophy (GA) and highlighted the importance of multimodal imaging to diagnose and monitor GA progression. Read More: https://lnkd.in/efcWQry2
-
-
The US Food and Drug Administration (FDA) has approved biosimilar to Eylea, aflibercept-mrbb (Ahzantive), for the treatment of patients with age-related neovascular (wet) macular degeneration (nAMD). The biosimilar has also been approved for treatment in patients with serious retinal diseases such as diabetic macular edema (DME), diabetic retinopathy (DR) and macular edema following retinal vein occlusion (RVO). Read More: https://lnkd.in/ezv6gnVE
FDA approves Formycon’s biosimilar to Eylea, aflibercept-mrbb (Ahzantive)
ophthalmologytimes.com
-
An overview of real-world geographic atrophy data: Durga Borkar, MD, MMCi, recently discussed the quality data (Qdata, Verana Health) gathered on geographic atrophy as well as the GATHER 1 and GATHER 2 data. Read more: https://ow.ly/YP1V50StP9Q
-
-
Repeated 0.1-ml intravireal injections of lampalizumab (RG 7417, Genentech), antigen-binding fragment of a humanized monoclonal antibody that inhibits complement factor D seem to be associated with a low risk of elevated intraocular pressure (IOP) in patients with geographic atrophy (GA), according to Neil Bressler, MD, and colleagues. He is from Johns Hopkins University School of Medicine, Baltimore. Historically, anti-vascular endothelial growth factor (VEGF) agents have been reported to cause IOP elevations that return to normal after about 30 minutes following 0.05-ml injections. However, the IOP elevations have become chronic in a small percentage of patients. Read More: https://ow.ly/9WVO50StPih
Low risk of elevated IOP with lampalizumab for geographic atrophy over 1 year
ophthalmologytimes.com